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BRIEF RESEARCH REPORTSCoronary artery bypass grafting is superior to first-generation
drug-eluting stents for unprotected left main coronary artery disease:
An updated meta-analysis of 4 randomized, controlled trialsUmberto Benedetto, MD, PhD,a Colin Ng, MBBS,a Robert Smith, MD,b and
Shahzad G. Raja, MRCS, FRCS(C-Th)a; on behalf of the Cardiac Outcomes Meta-Analysis (COMET)
Group, London, United KingdomThe optimal treatment approach for patients with unpro-
tected left main coronary artery (ULMCA) disease still
remains unclear.1 In recent years, as a result of the advent
of first-generation drug-eluting stents (DESs), restenosis
rates have decreased relative to conventional bare metal
stents, and the range of applications of percutaneous
coronary intervention for ULMCA disease has been
expanded.1 Several randomized, controlled trials (RCTs)
comparing coronary artery bypass grafting (CABG) with
stenting2-5 have recently been published, but the results
are inconclusive. We aimed to get insights into the
treatment of ULMCA disease by conducting an updated
meta-analysis and metaregression of the recent RCTs.
MATERIALS AND METHODS
MEDLINE (PubMed) was searched for RCTs that compared outcomes of
stentingwithDESversus those ofCABGin the treatment ofULMCAdisease.
For each study, data regarding all-cause mortality and the incidences of
myocardial infarction, stroke, repeat revascularization, and the composite
end point of major adverse cardiac and cerebrovascular events (MACCEs)
were used to generate odds ratios (ORs) for stenting relative to CABG
(with<1 favoring stenting and>1 favoringCABG).Apooled summaryeffect
estimatewas calculated bymeans of theMantel-Haenszel method. Between-
study heterogeneity was analyzed bymeans of the I2 index. A random effects
model was used for I2 values of at least 50%. Subgroup analysis was used to
investigate the effects of follow-up duration and SYNTAX (SYNergy be-
tween PCI with TAXUS and Cardiac Surgery) score on clinical outcomes.
RESULTS
A total of 4 RCTs2-5 were identified (Table 1) that enrolled
a total of 1611 individuals randomly assigned to undergo
CABG (n ¼ 802) or stenting (n ¼ 809). In 3 studies,2-4
first-generation DESs only (sirolimus- or paclitaxel-eluting
stents) were used. In 1 study,5 both bare metal stents and
DESs were used. Follow-up ranged from 1 to 5 years. No
RCTs comparing second-generation DESs with CABGFrom the Departments of Cardiac Surgerya and Cardiology,b Harefield Hospital,
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COMBAT (PREmier of RandomizedCOMparison ofBypass
Surgery Versus AngioplasTy Using Sirolimus-Eluting Stent
in Patients With Left Main Coronary Artery Disease) trial,4
reported on the MACCE rates in high (n ¼ 464) and low to
intermediate (n ¼ 795) SYNTAX score groups, although
different cutoffs were used (33 and 30, respectively).
Pooled estimates showed that stenting was comparable to
CABG in terms of all-cause death (OR, 0.79; 95% CI,
0.54-1.15; P ¼ .21; I2 ¼ 0%) and myocardial infarction
(OR, 1.49; 95% CI, 0.88-2.50; P¼ .14; I2¼ 0%). Stenting
was associated with a reduced risk of stroke (OR, 0.33;
95%, CI, 0.14-0.77; P ¼ .01; I2 ¼ 0%) but an increased
risk of repeat revascularization (OR 2.21; 95% CI, 1.62-
3.00; P<.00001; I2 ¼ 0%). Overall, stenting was signifi-
cantly associated with a higher rate of MACCEs (OR,
1.39; 95% CI, 1.09-1.77; P ¼ .009; I2 ¼ 0%; Figure 1).
Subgroup analysis for MACCE rate according to follow-
up duration showed that the stenting was significantly infe-
rior to CABG in studies with a follow-up longer than 1
year2-4 (OR, 1.41; 95% CI, 1.08-1.85; P ¼ .01; I2 ¼ 0%),
whereas this disadvantage was less evident in studies3-5
with a follow-up within 1 year (OR, 1.30; 95% CI, 0.74-
2.26; P ¼ .36; I2 ¼ 0%).
Subgroup analysis of the MACCE rate according to the
SYNTAX score (Figure 1) suggested that the inferiority
of stenting relative to CABG was particularly evident for
patients with high SYNTAX scores (OR, 1.93; 95% CI,
1.26-2.96; P ¼ .002; I2 ¼ 0%), whereas the inferiority of
stenting was less consistent in patients with low to
intermediate SYNTAX scores (OR, 1.34; 95% CI,
0.67-2.68; P ¼ .4; I2 ¼ 61%).
Pooled estimates did not significantly change when
studies including DESs only2-4 were included (P ¼ .59,
P ¼ .07, P ¼ .02, P< .00001, and P ¼ .01 for all-cause
death, myocardial infarction, stroke, repeat revasculariza-
tion, and MACCEs, respectively).DISCUSSION
A recently published meta-analysis1 pooling data from
observational studies and RCTs concluded that there was
no significant difference in combined MACCEs between
DES and CABG, thus supporting the conclusion that DES
is a safe and durable alternative to CABG. Results fromgery c November 2014
TABLE 1. Study overview
Study Year Size Male Mean age (y) Diabetes Mean SYNTAX score Type of stent FU
Morice et al,2
SYNTAX trial
2014 705 DES, 72%;
CABG, 76%
DES, 65;
CABG, 66
DES, 24%;
CABG, 26%
DES, 28.1;
CABG, 26.7
PES 5 y
Boudriot et al3 2011 201 DES, 72%;
CABG, 77%
DES, 66;
CABG, 69
DES, 40%;
CABG, 33%
DES, 24.0;
CABG, 23.0
SES 1 y
Park et al,4
PRECOMBAT
2011 600 DES, 76%;
CABG, 77%
DES, 62;
CABG, 63
DES, 34%;
CABG, 30%
DES, 24.4;
CABG, 25.8
SES 2 y
Buszman et al,5
LE MANS study
2008 105 Stent, 60%;
CABG, 73%
Stent, 60;
CABG, 61
Stent, 19%;
CABG, 17%
Stent, 25.2;
CABG, 24.7
DES,* 35%;
BMS, 65%
1 y
FU, Follow-up; DES, drug-eluting stent; CABG, coronary artery bypass grafting; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent; BMS, bare metal stent. *Type not
specified.
Brief Research Reportsobservational studies are likely to be distorted by patients se-
lection bias, however, and meta-analyses of RCTs remain the
standard criterion to summarize evidence. In addition, no pre-
vious meta-analysis has included the recently published
5-year follow-up SYNTAX trial results.2FIGURE 1. Forest plot for major adverse cardiac and cerebrovascular events i
grafting (CABG) groups. Asterisk indicates data available from SYNTAX2 and P
LM, left main coronary artery disease.
The Journal of Thoracic and CarAccording to our findings, CABG appears to be superior
to first-generation DESs in the treatment of ULMCA
disease by significantly reducing the overall incidence
of MACCEs, mainly driven by reduction in further
revascularization. The superiority of CABG seems to ben percutaneous coronary intervention (PCI) versus coronary artery bypass
RECOMBAT4 trials only.M-H, Mantel-Haenszel; CI, confidence interval;
diovascular Surgery c Volume 148, Number 5 2431
Brief Research Reportsparticularly evident among patients with complex lesions.
Efforts should be undertaken to reduce the incidence of
stroke, however, which remains higher in patients
undergoing CABG. Aortic ‘‘no touch’’ off-pump CABG
has been recently proposed as a means of minimizing the
risk of perioperative stroke. The rate of off-pump surgery
varied among the trials included, ranging from 1.8%5 to
63.8%.4 A trend toward an increased rate of stroke was
found among patients undergoing CABG regardless of the
rate of off-pump surgery. No data were available on
manipulation of the ascending aorta or the use of epiaortic
scanning, however, so whether off-pump surgery would
truly be beneficial cannot be evaluated, and further studies
are needed.
Despite these limitations, this meta-analysis demon-
strates a significant reduction in repeated revascularization
with CABG, which outweighs its detrimental increase in
stroke rate. Only first-generation DESs were used in allFrom the Department of Surgery, Columbia University Medical Center,
New York, NY.
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conclusions for second-generation devices.References
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538-45.Single-center experience with a minimally invasive apicoaxillary
external ventricular assist deviceElissa Landes, MD, Yoshifumi Naka, MD, PhD, Koji Takeda, MD, PhD, and Hiroo Takayama, MD, PhD,
New York, NYMechanical circulatory support (MCS) devices have become
more popular in the treatment of cardiogenic shock (CS).
Options for emergency support include venoarterial extra-
corporeal membrane oxygenation, percutaneous ventricular
assist devices (VADs), and surgical VADs. Among MCS
devices, surgical VADs have the advantage of providing
sufficient circulatory support1; however, the standard tech-
nique requires implantation through a median sternotomy.2
Previously, we described a unique configuration of the
CentriMag (Thoratec Corporation, Pleasanton, Calif) left
VAD (LVAD) that allowed rapid off-pump placement
without performing a sternotomy.3 Here we present a seriesof cases of patients who received this external apicoaxillary
LVAD (AA-LVAD) as a bridge to decision.MATERIALS AND METHODS
Our institutional review board approved this study. Between January
2007 and December 2013, a series of 198 patients underwent CentriMag
VAD insertion for CS at our institution. The cases of 7 patients who
received AA-LVADs were reviewed.
Indications
Indications for AA-LVAD placement include patients in CS who require
VAD support but do not meet criteria for durable MCS device implantation
at the time of evaluation. Our default strategy for device therapy in CS is to
insert a short-term biventricular VAD, so this technique is reserved for
those who can succeed with isolated LVAD support. Patients with CS
who have peripheral vascular disease that precludes the use of a
percutaneous MCS may also be considered for this support. Patients are
excluded if there are mechanical obstacles to cannulation of their axillary
artery or left ventricular apex.
Technique
The details of AA-LVAD implantation are described elsewhere.3
Briefly, after intubation, the axillary artery (right or left) is exposed through
a small infraclavicular incision, and the left ventricular apex is exposed
through a left anterior thoracotomy. Heparin of 5 to 10,000 units is given.
An 8-mm Dacron polyester fabric graft is sewn end to side to the
axillary artery, and the arterial cannula (24F EOPA; Medtronic, Inc,gery c November 2014
